Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 15, 2006 - Issue 2
Submit an article Journal homepage
280
Views
31
CrossRef citations to date
0
Altmetric
Drug Evaluation

Current therapeutic uses of lenalidomide in multiple myeloma

Teru Hideshima Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. [email protected]
,
Paul G Richardson Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. [email protected]
&
Kenneth C Anderson Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. [email protected]
Pages 171-179 | Published online: 24 Jan 2006

Citations (31)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Douglas W. McMillin & Constantine S. Mitsiades. (2012) High-throughput approaches to discover novel immunomodulatory agents for cancer. OncoImmunology 1:8, pages 1406-1408.
Read now
Ali Tabarroki & Ramon V Tiu. (2012) Immunomodulatory agents in myelofibrosis. Expert Opinion on Investigational Drugs 21:8, pages 1141-1154.
Read now
Iris Breitkreutz & Kenneth C Anderson. (2008) Thalidomide in multiple myeloma – clinical trials and aspects of drug metabolism and toxicity. Expert Opinion on Drug Metabolism & Toxicology 4:7, pages 973-985.
Read now

Articles from other publishers (28)

Yue Wu, Xiangjun Shi, Xinchen Yao & Xinru Du. (2023) Biological research on the occurrence and development of multiple myeloma and its treatment. Immunity, Inflammation and Disease 11:5.
Crossref
Junichi Yamamoto, Tomoko Asatsuma‐Okumura, Takumi Ito, Yuki Yamaguchi & Hiroshi Handa. 2022. Protein Homeostasis in Drug Discovery. Protein Homeostasis in Drug Discovery 283 315 .
Hossein Harati, Ali Morsali, Mohammad Reza Bozorgmehr & S. Ali Beyramabadi. (2021) β-cyclodextrin-lenalidomide anticancer drug delivery nanosystem: A quantum chemical approach. Journal of Molecular Liquids 344, pages 117762.
Crossref
Punna VenkateshwarluMehul M. Patel. (2021) A Review: Method Development Validation and Degradation Studies of some Anticancer Drugs. Research Journal of Pharmacy and Technology, pages 5443-5448.
Crossref
Punna VenkateshwarluMehul M. Patel. (2021) Method Development and Validation of Degradation Studies of Lenalidomide by RP-HPLC. Research Journal of Pharmacy and Technology, pages 4281-4286.
Crossref
R. Gopinath, S. T. Narenderan, M. Kumar & B. Babu. (2019) Development and validation of a liquid chromatography-tandem mass spectrometric method for the determination of lenalidomide in human plasma and its application on bioequivalence studies. Journal of Analytical Science and Technology 10:1.
Crossref
Wenli Zuo, Xinghu Zhu, Jingke Yang, Zhenyang Mei, Mei Deng, Quande Lin, Yongping Song & Qingsong Yin. (2017) Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma. Medicine 96:1, pages e5787.
Crossref
Sara M. Tinsley, Sandra E. Kurtin & Jean A. Ridgeway. (2015) Practical Management of Lenalidomide-Related Rash. Clinical Lymphoma Myeloma and Leukemia 15, pages S64-S69.
Crossref
Muzaffar Iqbal, Tanveer A Wani, Nasr Y Khalil & Ibrahim A Darwish. (2013) Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. Chemistry Central Journal 7:1.
Crossref
Nasr Y Khalil, Ibrahim A Darwish, Tanveer A Wani & Abdel-Rahman A Al-Majed. (2013) Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine. Chemistry Central Journal 7:1.
Crossref
Beatrice Nardone, Shenhong Wu, Benjamin C. Garden, Dennis P. West, Lilian M. Reich & Mario E. Lacouture. (2013) Risk of Rash Associated With Lenalidomide in Cancer Patients: A Systematic Review of the Literature and Meta-analysis. Clinical Lymphoma Myeloma and Leukemia 13:4, pages 424-429.
Crossref
Imran AliWaseem A Wani, Ashanul Haque & Kishwar Saleem. (2013) Glutamic acid and its derivatives: candidates for rational design of anticancer drugs. Future Medicinal Chemistry 5:8, pages 961-978.
Crossref
KARAM KIM, SUNGKWAN AN, HWA JUN CHA, YEONG MIN CHOI, SUNG JIN CHOI, IN-SOOK AN, HONG GHI LEE, YOO HONG MIN, SU-JAE LEE & SEUNGHEE BAE. (2013) Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells. Oncology Letters 5:2, pages 588-592.
Crossref
Anuj Mahindra, Jacob Laubach, Constantine Mitsiades & Paul Richardson. 2013. Advances in Biology and Therapy of Multiple Myeloma. Advances in Biology and Therapy of Multiple Myeloma 215 228 .
Ibrahim A Darwish, Nourh Z Alzoman, Reem M Abuhejail & Tilal E El-Samani. (2012) Synthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myeloma. Chemistry Central Journal 6:1.
Crossref
Ibrahim A Darwish, Nasr Y Khalil, Ahmed H Bakheit & Nourh Z Alzoman. (2012) A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine. Chemistry Central Journal 6:1.
Crossref
Douglas W. McMillin, Jake Delmore, Joseph M. Negri, Matthew Vanneman, Shohei Koyama, Robert L. Schlossman, Nikhil C. Munshi, Jacob Laubach, Paul G. Richardson, Glenn Dranoff, Kenneth C. Anderson & Constantine S. Mitsiades. (2012) Compartment-specific bioluminescence imaging platform for the high-throughput evaluation of antitumor immune function. Blood 119:15, pages e131-e138.
Crossref
Sagar Lonial. (2009) Future directions in immunomodulatory therapy. Medical Oncology 27:S1, pages 62-66.
Crossref
Robert J. Greenstein, Liya Su & Sheldon T. Brown. (2009) On the effect of thalidomide on Mycobacterium avium subspecies paratuberculosis in culture. International Journal of Infectious Diseases 13:5, pages e254-e263.
Crossref
Yutaka Ohkawa & Keisuke Aiba. (2009) 3. Molecular-targeted Drugs. 1) Indications and the Application of Molecular-targeted Drugs in Hematological Diseases. Nihon Naika Gakkai Zasshi 98:8, pages 1908-1917.
Crossref
Antonio PalumboPatrizia FalcoPaolo CorradiniAntonietta FalconeFrancesco Di RaimondoNicola GiulianiClaudia CrippaGiovannino CicconePaola OmedèMaria Teresa AmbrosiniFrancesca GaySara BringhenPellegrino MustoRobin FoàRobert KnightJerome B. ZeldisMario BoccadoroMaria Teresa Petrucci. (2007) Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network. Journal of Clinical Oncology 25:28, pages 4459-4465.
Crossref
Joell J. Gills, Jaclyn LoPiccolo, Junji Tsurutani, Robert H. Shoemaker, Carolyn J.M. Best, Mones S. Abu-Asab, Jennifer Borojerdi, Noel A. Warfel, Erin R. Gardner, Matthew Danish, M. Christine Hollander, Shigeru Kawabata, Maria Tsokos, William D. Figg, Patricia S. Steeg & Phillip A. Dennis. (2007) Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo . Clinical Cancer Research 13:17, pages 5183-5194.
Crossref
Carmelo Carlo-Stella, Anna Guidetti, Massimo Di Nicola, Cristiana Lavazza, Loredana Cleris, Daniela Sia, Paolo Longoni, Marco Milanesi, Michele Magni, Zoltan Nagy, Paolo Corradini, Antonino Carbone, Franca Formelli & Alessandro M. Gianni. (2007) IFN-γ Enhances the Antimyeloma Activity of the Fully Human Anti–Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3. Cancer Research 67:7, pages 3269-3275.
Crossref
Joseph D. Tariman. (2007) Current Therapies for Multiple Myeloma. Journal of Infusion Nursing 30:2, pages 113-118.
Crossref
Ellen C. Mullen & Michael Wang. (2007) Recognizing Hyperviscosity Syndrome in Patients With Waldenstrom Macroglobulinemia. Clinical Journal of Oncology Nursing 11:1, pages 87-95.
Crossref
Shridhar Hegde & Michelle Schmidt. 2007. Annual Reports in Medicinal Chemistry Volume 42. Annual Reports in Medicinal Chemistry Volume 42 505 554 .
Irene M. Ghobrial, Leslie Lockridge & Paul G. Richardson. (2006) The emerging role of novel therapeutic agents in the management of patients with multiple myeloma. Community Oncology 3:9, pages 575-582.
Crossref
. (2006) Current Awareness in Hematological Oncology. Hematological Oncology 24:3, pages 166-173.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.